Asper Biogene ISO 15189:2022 accreditation update

The Estonian Standardization and Accreditation Center conducted a regular audit in 2026 and confirms that Asper Biogene OÜ meets the requirements of EVS-EN ISO 15189:2022 as a medical laboratory in the field of genetics. Into the list of accredited tests were added:

  • Determination of thrombophilia-related changes using NGS analysis,
  • Determination of hypolactasia-related changes using NGS and Sanger analysis
»
Metabolic disorders portfolio update

Hereditary pancreatitis test has been added to Asper metabolic disorders portfolio. More information can be found here.

»
Neuro update 04.2026

Genes associated with neuroacanthocytosis were added to dystonia and Parkinson disease panels

»
Asper metabolics update

Monogenic obesity gene panel  was added to Asper Metabolic Disorders portfolio.  See also galactosemia, lactose intolerance and celiac disease.

»
Familial hyperchlesterolaemia update

The analysis of familial hypercholesterolaemia now includes 8 genes.

»
Myotonia Congenita in Neurogenetics

Myotonia Congenita NGS panel was added into Asper Biogene’s Neurogenetics portfolio

»
Asper cardiogenetics update

There have been several updates among Asper Cardiogenetics

»
Asper Immunogenetics portfolio news

We have a brand new portfolio!

»
Dysmorphology update

Asper Dysmorphology now offer panels for Joubert Syndrome, Ehler-Danlos Syndrome, Bardet-Biedli Syndrome and many more.

»
Mitochondrial Genome Sequencing

The Cardiogenetics, Metabolic Disorders, and Otogenetics panels now offer mitochondrial genome sequencing.

»